Salix Pharmaceuticals Ltd

Salix Pharmaceuticals — Merger or Acquisition (July 2014)

9 slides from Salix Pharmaceuticals's merger presentation, Jul 9, 2014

  1. Slide 1: Salix Combines with Cosmo Tech

    July 8, 2014 Exhibit 99.1 Proprietary and Confidential • For Internal Use Only Salix Combines with Cosmo Tech We have a One Tract mind.

  2. Slide 2: Forward-Looking Statement

    Please Note: The statements provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, our expec

  3. Slide 3: Strategic Rationale

    • – Captures full value of Uceris ® by eliminating all the Uceris royalty and milestone payments, and modifying the supply agreement, substantially improving product profitability – U.S. patents for rifamycin MMX® and methylene blue MMX® enhance and diversify the Salix development pipeline • Substan

  4. Slide 4: Proposed Transaction Terms

    Proprietary and Confidential • For Internal Use Only Structure Consideration Management and Governance Timing / Approvals Proposed Transaction Terms • New company name will be Salix Pharmaceuticals, plc which will be headquartered in Raleigh, NC and incorporated in Ireland • Salix shareholders will

  5. Slide 5: Cosmo Pharmaceuticals: An Overview

    • Specialty pharmaceutical company focused on the development of innovative treatments for the GI tract such as inflammatory bowel disease, colon infections and diagnostics for the colon • Publicly-traded, headquartered in Lainate, Italy, listed on the Swiss Exchange – Owns 100% of Cosmo Technologie

  6. Slide 6: Key Product Additions to the Salix Development Pipeline

    • – Travelers’ / infectious diarrhea – Currently in Phase 3: Expected U.S. launch in 2H 2017 – Projected peak year sales: ~$130 million • – Treatment of acute uncomplicated diverticulitis in adults 18 years or older – Currently in Phase 2: Expected U.S. launch in 1H 2019 – Projected peak year sales:

  7. Slide 7: Expands the Salix Development Pipeline from 9 to 12

    Early Development Phase 2 Phase 3 NDA / BLA Filing * Denotes post Complete Response Letter activity From Cosmo Proprietary and Confidential • For Internal Use Only Early Development Phase 2 Phase 3 NDA / BLA Filing Rifaximin SSD Indication: Prevention of Decompensated Liver Event SAN-300 Indication:

  8. Slide 8: Proposed Transaction Benefits Summary

    • – Expands product development pipeline • U.S. patents for rifamycin MMX and methylene blue MMX – Specific rights of negotiation for all Cosmo products in U.S. – • – Increases competitive positioning for future M&A and product licensing efforts – Meaningful opportunity for improved tax planning • L

  9. Slide 9: Additional Information and Where to Find It

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction and required stockholder approval, Cosmo Pharmaceuticals S.p.A, Cosmo Technologies Limited and Salix wi

Salix Pharmaceuticals — Merger or Acquisition (July 2014) on 6ix